MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies

Seo, Hyun Ah; Moeng, Sokviseth; Sim, Seokmin; Kuh, Hyo-Jeong; Choi, Soo Young; Park, Jong Kook

doi:10.3390/cells9010029

Cited by 50 publications

(40 citation statements)

References 198 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date no clinical trials are underway and some research groups are testing the combination of miRNA-based therapy with other anti-cancer therapies (miRNA-based combinatorial cancer therapy) [61]. This approach is an attractive perspective for intervening in the event that a tumor manifests the acquired therapeutic resistance which leads to cancer relapse.…”

Section: Mirnas Inhibited By Mutant P53mentioning

confidence: 99%

“…miRNAs are able to target several genes associated with the signaling pathways controlling therapeutic resistance. miRNA-based combinatorial cancer therapy might overcome the therapeutic resistance present in different types of cancer [61]. miR-223-3p lung [63] let-71 breast [64] It has been shown that mut-p53 proteins down-regulate miR-223 expression in breast and colon cancer cell lines [62].…”

Section: Mirnas Inhibited By Mutant P53mentioning

confidence: 99%

See 1 more Smart Citation

The Impact of Mutant p53 in the Non-Coding RNA World

Agostino

2020

Biomolecules

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), micro RNAs (miRNAs), and extracellular RNAs (exRNAs) are new groups of RNAs with regulation activities that have low or no protein-coding ability. Emerging evidence suggests that deregulated expression of these non-coding RNAs is associated with the induction and progression of diverse tumors throughout epigenetic, transcriptional, and post-transcriptional modifications. A consistent number of non-coding RNAs (ncRNAs) has been shown to be regulated by p53, the most important tumor suppressor of the cells frequently mutated in human cancer. It has been shown that some mutant p53 proteins are associated with the loss of tumor suppressor activity and the acquisition of new oncogenic functions named gain-of-function activities. In this review, we highlight recent lines of evidence suggesting that mutant p53 is involved in the expression of specific ncRNAs to gain oncogenic functions through the creation of a complex network of pathways that influence each other.Biomolecules 2020, 10, 472 2 of 15 heterotetrameric mut-p53/wt-p53 complex can inhibit the function of the remaining wt-p53 in tumor suppression [8,9]. Most of the missense mutations occur in the p53 DNA-binding region and can be classified as either contact mutations (as p53R248 and p53R273 interfere directly with DNA binding) or conformational mutations (as p53R175 induces local or global conformational distortions) [5,9].Six hotspot mutations are the most represented in the cancers. These include R175, G245, R248, R249, R273, and R282, which make up about 30% of all mutations in TP53 covering all human cancer types [8][9][10]. However, due to cancer genome sequencing tools, many other different TP53 mutations have been discovered. mut-p53 GOF has been demonstrated by numerous cell-based experiments such as by ectopic expression of mut-p53 proteins in p53-null human tumor cells or knockdown of endogenous mut-p53 in cells containing only one allele of mutant p53, as well as in mutant p53 knock-in mouse models [5,[8][9][10]. Genome sequencencing has highlighted that more than 91% of TP53-mutant cancers exhibit loss of the second allele (LOH) by mutation or DNA deletion [11].Many mut-p53 GOF activities have been identified as tumor cell proliferation, survival, migration and invasion, enhancing chemoresistance, disrupting proper tissue architecture, inducing cancer metabolism (Warburg effect and lipid metabolism), and increasing genomic instability and mitochondrial dysfunction [5,[10][11][12][13][14][15] (Figure 1).

show abstract

Section: Mirnas Inhibited By Mutant P53mentioning

confidence: 99%

Section: Mirnas Inhibited By Mutant P53mentioning

confidence: 99%

The Impact of Mutant p53 in the Non-Coding RNA World

Agostino

2020

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Abnormal expression of miRNAs is related to various biological modifications, such as apoptosis, cell differentiation, and carcinogenesis (Su et al, 2017;Truong et al, 2017). More and more studies show that miRNAs play a necessary role in the occurrence and development of a variety of cancers, including lung cancer, breast cancer, and colon cancer (Seo et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs Associated With Colon Cancer: New Potential Prognostic Markers and Targets for Therapy

Zhu

Xü

Liu

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a kind of non-coding RNA (ncRNA) that regulate the expression of target genes and play a role in the occurrence and development of cancers. Colon cancer (COAD) is the second most common cause of cancer-related mortality. However, the prognostic value of miRNAs in COAD is still confusing. In this study, we obtain miRNAs and messenger RNAs (mRNAs) expression profiles of COAD from the Cancer Genome Atlas (TCGA) database. After preliminary data screening and preprocessing, we acquire the expression data of 894 miRNAs and 17,019 mRNAs. Then, compared with the normal samples, 39 upregulated miRNAs and 54 downregulated miRNAs are identified by differential expression analysis. Furthermore, we obtain 1,487 upregulated mRNAs and 2,847 downregulated mRNAs. We confirm nine key miRNAs related to the survival rate of COAD patients. Moreover, by using bioinformatics methods, we get 461 common genes from both the target genes of these nine key miRNAs and differentially expressed mRNAs. Through analyzing the protein-protein interaction (PPI) network of these 461 common genes and survival analysis, we confirm five hub genes as promising biomarkers for COAD prognosis. It is worth mentioning that no previous reports have found that PGR and KCNB1 are related to COAD. We expect these key miRNAs and hub genes will provide a new way for the study of COAD.

show abstract

“…Chemotherapy and radiotherapy are currently used in cancer treatments; however, they are moderately effective, leading to the insufficient regression and remission of cancer. Moreover, the adverse effects of chemotherapy, such as toxicity to normal cells and therapeutic resistance, restrict the utilization of anti-cancer agents [ 2 , 3 , 4 ]. Therefore, intensive efforts have been made to continuously search for and develop new agents and strategies for cancer therapy with better efficacy.…”

Section: Introductionmentioning

confidence: 99%

Participation of MicroRNAs in the Treatment of Cancer with Phytochemicals

et al. 2020

Self Cite

View full text Add to dashboard Cite

Cancer is a global health concern and one of the main causes of disease-related death. Even with considerable progress in investigations on cancer therapy, effective anti-cancer agents and regimens have thus far been insufficient. There has been compelling evidence that natural phytochemicals and their derivatives have potent anti-cancer activities. Plant-based anti-cancer agents, such as etoposide, irinotecan, paclitaxel, and vincristine, are currently being applied in medical treatments for patients with cancer. Further, the efficacy of plenty of phytochemicals has been evaluated to discover a promising candidate for cancer therapy. For developing more effective cancer therapy, it is required to apprehend the molecular mechanism deployed by natural compounds. MicroRNAs (miRNAs) have been realized to play a pivotal role in regulating cellular signaling pathways, affecting the efficacy of therapeutic agents in cancer. This review presents a feature of phytochemicals with anti-cancer activity, focusing mainly on the relationship between phytochemicals and miRNAs, with insights into the role of miRNAs as the mediators and the regulators of anti-cancer effects of phytochemicals.

show abstract

MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies

Cited by 50 publications

References 198 publications

The Impact of Mutant p53 in the Non-Coding RNA World

The Impact of Mutant p53 in the Non-Coding RNA World

MicroRNAs Associated With Colon Cancer: New Potential Prognostic Markers and Targets for Therapy

Participation of MicroRNAs in the Treatment of Cancer with Phytochemicals

Contact Info

Product

Resources

About